CTOs on the Move

Lacerta Therapeutics

www.lacertatherapeutics.com

 
Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Lacerta Therapeutics raised $30M on 08/09/2018

Similar Companies

SGS

SGS is the world`s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 95,000 employees, SGS operates a network of over 2,400 offices and laboratories around the world.

Metagenomi

Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

GigaGen

GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world`s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.

Farkas IRM

Farkas IRM is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood test to transform the care of cancer patients. The Company`s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge and backed by multiple high calibre publications. Its lead product, InVisionFirst™-Lung, is commercially available and provides molecular insights that enable clinicians to make more informed treatment decisions for NSCLC patients. Inivata is partnering with pharmaceutical and biotechnology companies on InVisionFirst-Lung and its wider platform, which is applicable to a range of cancer types. The Company has a CLIA laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK.